GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (FRA:VX1) » Definitions » Cyclically Adjusted Price-to-FCF

Vertex Pharmaceuticals (FRA:VX1) Cyclically Adjusted Price-to-FCF : 62.59 (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted Price-to-FCF?

As of today (2024-05-17), Vertex Pharmaceuticals's current share price is €403.05. Vertex Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €6.44. Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 62.59.

The historical rank and industry rank for Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

FRA:VX1' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 55.85   Med: 72.55   Max: 924.7
Current: 63.67

During the past years, Vertex Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 924.70. The lowest was 55.85. And the median was 72.55.

FRA:VX1's Cyclically Adjusted Price-to-FCF is ranked worse than
57.69% of 104 companies
in the Biotechnology industry
Industry Median: 55.165 vs FRA:VX1: 63.67

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €3.729. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €6.44 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vertex Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 384.37 111.35 68.93 60.17 64.67

Vertex Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.90 61.40 55.45 64.67 60.40

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Vertex Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=403.05/6.44
=62.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Vertex Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.729/131.7762*131.7762
=3.729

Current CPI (Mar. 2024) = 131.7762.

Vertex Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.440 100.560 -0.577
201409 -0.319 100.428 -0.419
201412 -0.668 99.070 -0.889
201503 -0.898 99.621 -1.188
201506 -0.458 100.684 -0.599
201509 -0.261 100.392 -0.343
201512 0.063 99.792 0.083
201603 -0.100 100.470 -0.131
201606 0.091 101.688 0.118
201609 0.188 101.861 0.243
201612 0.502 101.863 0.649
201703 0.957 102.862 1.226
201706 0.581 103.349 0.741
201709 -0.060 104.136 -0.076
201712 0.608 104.011 0.770
201803 0.701 105.290 0.877
201806 0.967 106.317 1.199
201809 1.189 106.507 1.471
201812 1.011 105.998 1.257
201903 1.043 107.251 1.282
201906 1.524 108.070 1.858
201909 1.082 108.329 1.316
201912 1.473 108.420 1.790
202003 2.735 108.902 3.309
202006 3.441 108.767 4.169
202009 2.356 109.815 2.827
202012 1.395 109.897 1.673
202103 2.727 111.754 3.216
202106 -0.794 114.631 -0.913
202109 2.863 115.734 3.260
202112 3.215 117.630 3.602
202203 3.143 121.301 3.414
202206 3.973 125.017 4.188
202209 3.508 125.227 3.691
202212 3.789 125.222 3.987
202303 3.078 127.348 3.185
202306 3.810 128.729 3.900
202309 4.415 129.860 4.480
202312 0.417 129.419 0.425
202403 3.729 131.776 3.729

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vertex Pharmaceuticals  (FRA:VX1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Vertex Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (FRA:VX1) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (FRA:VX1) Headlines

No Headlines